Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections – Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.
H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs).
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 8, 7, 1, 41 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 11 and 3 molecules, respectively.
Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AbbVie Inc
Akshaya Bio Inc
Altimmune Inc
Antigen Express Inc
Beijing Minhai Biotechnology Co Ltd
CEL-SCI Corp
Cilian AG
Cocrystal Pharma Inc
ContraFect Corp
Curevac AG
EpiVax Inc
Etubics Corp
Gemmus Pharma Inc
Genentech Inc
iBio Inc
ILiAD Biotechnologies LLC
Inovio Pharmaceuticals Inc
Johnson & Johnson
Kineta Inc
Kyowa Hakko Kirin Co Ltd
Lakewood-Amedex Inc
Medicago Inc
MedImmune LLC
Microbiotix Inc
Mucosis BV
NanoViricides Inc
NewLink Genetics Corp
Novavax Inc
OPKO Health Inc
PeptiDream Inc
Prommune Inc
Protein Sciences Corp
Recce Ltd
Sanofi Pasteur SA
Sarepta Therapeutics Inc
SK Chemicals Co Ltd
Takeda Pharmaceutical Company Ltd
TechnoVax Inc
Touchlight Genetics Ltd
Vaccibody AS
Vaxart Inc
Vironova AB
Visterra Inc
Zydus Cadila Healthcare Ltd
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Influenza A Virus, H1N1 Subtype Infections – Overview 9
Influenza A Virus, H1N1 Subtype Infections – Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 15
Products under Development by Companies 17
Products under Development by Universities/Institutes 22
Influenza A Virus, H1N1 Subtype Infections – Therapeutics Assessment 23
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Influenza A Virus, H1N1 Subtype Infections – Companies Involved in Therapeutics Development 31
AbbVie Inc 31
Akshaya Bio Inc 31
Altimmune Inc 32
Antigen Express Inc 32
Beijing Minhai Biotechnology Co Ltd 33
CEL-SCI Corp 33
Cilian AG 34
Cocrystal Pharma Inc 34
ContraFect Corp 35
Curevac AG 35
EpiVax Inc 36
Etubics Corp 36
Gemmus Pharma Inc 37
Genentech Inc 37
iBio Inc 38
ILiAD Biotechnologies LLC 38
Inovio Pharmaceuticals Inc 39
Johnson & Johnson 39
Kineta Inc 40
Kyowa Hakko Kirin Co Ltd 40
Lakewood-Amedex Inc 41
Medicago Inc 41
MedImmune LLC 42
Microbiotix Inc 42
Mucosis BV 43
NanoViricides Inc 43
NewLink Genetics Corp 44
Novavax Inc 44
OPKO Health Inc 45
PeptiDream Inc 45
Prommune Inc 46
Protein Sciences Corp 46
Recce Ltd 47
Sanofi Pasteur SA 47
Sarepta Therapeutics Inc 48
SK Chemicals Co Ltd 48
Takeda Pharmaceutical Company Ltd 49
TechnoVax Inc 49
Touchlight Genetics Ltd 50
Vaccibody AS 50
Vaxart Inc 51
Vironova AB 51
Visterra Inc 51
Zydus Cadila Healthcare Ltd 52
Influenza A Virus, H1N1 Subtype Infections – Drug Profiles 53
AE-AI vaccine – Drug Profile 53
AEA-35p – Drug Profile 54
Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza A Virus, H1N1 Subtype Infections – Drug Profile 55
Aspidasept – Drug Profile 56
AV-5027 – Drug Profile 57
AV-5080 – Drug Profile 58
CC-42344 – Drug Profile 59
cetylpyridinium chloride – Drug Profile 60
CF-401 – Drug Profile 61
CHOS-05 – Drug Profile 62
CiFlu – Drug Profile 63
diridavumab – Drug Profile 65
EP-67 – Drug Profile 67
ETBX-051 – Drug Profile 68
Flu-v – Drug Profile 69
Fluad (quadrivalent) – Drug Profile 71
Fludase – Drug Profile 72
FluGEM – Drug Profile 75
Gamma-Flu – Drug Profile 76
GP-1001 – Drug Profile 77
GP-1681 – Drug Profile 78
GREFLU/CAL – Drug Profile 80
H1N1 [A/Aichi/2/68] vaccine – Drug Profile 81
HB-36.6 – Drug Profile 82
IN-1 – Drug Profile 83
infectious disease vaccine – Drug Profile 84
Influ-nRNA – Drug Profile 85
influenza [strain A/H1N1] vaccine – Drug Profile 86
influenza [strain A/H1N1] vaccine – Drug Profile 88
influenza [strain A/H1N1] vaccine – Drug Profile 89
influenza [strain H1N1] (virus like particle) vaccine – Drug Profile 90
influenza [strain H1N1] vaccine – Drug Profile 91
influenza [strain H1N1] vaccine – Drug Profile 92
influenza [strain H1N1] vaccine – Drug Profile 93
influenza [strain H1N1] vaccine – Drug Profile 94
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine – Drug Profile 95
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine – Drug Profile 96
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine – Drug Profile 97
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine – Drug Profile 98
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine – Drug Profile 99
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine – Drug Profile 102
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine – Drug Profile 103
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine – Drug Profile 104
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine – Drug Profile 105
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine – Drug Profile 109
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine – Drug Profile 110
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine – Drug Profile 111
influenza [strains A/H1N1 + A/H3N2 + B] vaccine – Drug Profile 112
influenza [strains A/H1N1 + A/H5N1] vaccine – Drug Profile 113
influenza [strains A/H5N1 + A/H1N1] vaccine – Drug Profile 114
influenza vaccine – Drug Profile 115
INO-3510 – Drug Profile 116
JNJ-3872 – Drug Profile 118
KIN-1148 – Drug Profile 121
KIN-1400 – Drug Profile 123
LEAPS-H1N1-DC – Drug Profile 125
MBX-2329 – Drug Profile 126
MBX-2546 – Drug Profile 127
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections – Drug Profile 128
Nasovax – Drug Profile 129
NBP-607 – Drug Profile 131
NEO-8877 – Drug Profile 132
Nucleozin – Drug Profile 133
NVINF-1 – Drug Profile 134
NVINF-2 – Drug Profile 139
Oligonucleotide to Activate RIG-1 for Influenza A Virus H1N1 Infections – Drug Profile 142
PD-001 – Drug Profile 143
Peptides for Influenza Infections – Drug Profile 144
pertussis [strain BPZE1] vaccine – Drug Profile 145
PNSIA-28 – Drug Profile 147
PNSIA-49 – Drug Profile 148
radavirsen – Drug Profile 149
RECCE-327 – Drug Profile 151
RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection – Drug Profile 153
Small Molecules for Influenza A Virus H1N1 and H5N1 Infections – Drug Profile 154
Small Molecules for RSV and Influenza A Infections – Drug Profile 155
Small Molecules to Block M2 Channel for Influenza Infections – Drug Profile 156
Small Molecules to Inhibit Influenza A Endonuclease for H1N1 Infections – Drug Profile 157
Synthetic Peptides for Influenza, HSV and HIV Infections – Drug Profile 158
TVX-002 – Drug Profile 159
VH-244 – Drug Profile 160
VIS-410 – Drug Profile 161
VNFC-045 – Drug Profile 164
VNFC-051 – Drug Profile 165
VXAA-1.1 – Drug Profile 166
WLBU-2 – Drug Profile 168
Z-3G1 – Drug Profile 169
Influenza A Virus, H1N1 Subtype Infections – Dormant Projects 170
Influenza A Virus, H1N1 Subtype Infections – Discontinued Products 173
Influenza A Virus, H1N1 Subtype Infections – Product Development Milestones 174
Featured News & Press Releases 174
Appendix 186
Methodology 186
Coverage 186
Secondary Research 186
Primary Research 186
Expert Panel Validation 186
Contact Us 186
Disclaimer 187
List of Tables
Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by AbbVie Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Akshaya Bio Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Altimmune Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Antigen Express Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by CEL-SCI Corp, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Cilian AG, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Cocrystal Pharma Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by ContraFect Corp, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Curevac AG, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by EpiVax Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Etubics Corp, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Gemmus Pharma Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Genentech Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by iBio Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by ILiAD Biotechnologies LLC, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Johnson & Johnson, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Kineta Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Lakewood-Amedex Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Medicago Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by MedImmune LLC, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Microbiotix Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Mucosis BV, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by NanoViricides Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by NewLink Genetics Corp, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Novavax Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by OPKO Health Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by PeptiDream Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Prommune Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Protein Sciences Corp, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Recce Ltd, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Sanofi Pasteur SA, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Sarepta Therapeutics Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by SK Chemicals Co Ltd, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by TechnoVax Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Touchlight Genetics Ltd, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Vaccibody AS, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Vaxart Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Vironova AB, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Visterra Inc, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Dormant Projects, H1 2017
Influenza A Virus, H1N1 Subtype Infections – Dormant Projects, H1 2017 (Contd..1), H1 2017
Influenza A Virus, H1N1 Subtype Infections – Dormant Projects, H1 2017 (Contd..2), H1 2017
Influenza A Virus, H1N1 Subtype Infections – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
